[
  {
    "ts": null,
    "headline": "CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike",
    "summary": "CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.",
    "url": "https://finnhub.io/api/news?id=d8f08986b54f3855b6e0859d441e5a00a4be60e5773fa1dc73e0f496bae7cb4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765896900,
      "headline": "CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike",
      "id": 137807104,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.",
      "url": "https://finnhub.io/api/news?id=d8f08986b54f3855b6e0859d441e5a00a4be60e5773fa1dc73e0f496bae7cb4d"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA) Is Up 5.9% After EMA Backs New mNEXSPIKE Vaccine - Has The Bull Case Changed?",
    "summary": "The European Medicines Agency’s Committee for Medicinal Products for Human Use previously issued a positive opinion recommending marketing authorization of Moderna’s new COVID-19 vaccine, mNEXSPIKE (mRNA-1283), for individuals aged 12 and older, following Phase 3 data showing higher relative efficacy versus Spikevax. This potential EU approval would broaden Moderna’s respiratory vaccine lineup and regional footprint, partly counterbalancing pressure from weakening COVID-19 vaccine...",
    "url": "https://finnhub.io/api/news?id=c04e2bae8fa6bef5bae2eafb4dff31a155a3c22149bfebbea557ac6b63c8f6a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765894016,
      "headline": "Moderna (MRNA) Is Up 5.9% After EMA Backs New mNEXSPIKE Vaccine - Has The Bull Case Changed?",
      "id": 137807105,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The European Medicines Agency’s Committee for Medicinal Products for Human Use previously issued a positive opinion recommending marketing authorization of Moderna’s new COVID-19 vaccine, mNEXSPIKE (mRNA-1283), for individuals aged 12 and older, following Phase 3 data showing higher relative efficacy versus Spikevax. This potential EU approval would broaden Moderna’s respiratory vaccine lineup and regional footprint, partly counterbalancing pressure from weakening COVID-19 vaccine...",
      "url": "https://finnhub.io/api/news?id=c04e2bae8fa6bef5bae2eafb4dff31a155a3c22149bfebbea557ac6b63c8f6a6"
    }
  },
  {
    "ts": null,
    "headline": "‘Zombie’ biotech buyer Xoma to acquire Generation Bio",
    "summary": "The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery technology that had shown promise in preclinical tests.",
    "url": "https://finnhub.io/api/news?id=93eca9f33f29cf0bcba8e968fbdcf22411cd0160210fbc1cdbac6a21c903cd9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765872180,
      "headline": "‘Zombie’ biotech buyer Xoma to acquire Generation Bio",
      "id": 137807106,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery technology that had shown promise in preclinical tests.",
      "url": "https://finnhub.io/api/news?id=93eca9f33f29cf0bcba8e968fbdcf22411cd0160210fbc1cdbac6a21c903cd9f"
    }
  }
]